Shots:

• Arena to get $1.2B as total deal value- including $800M upfront plus $400M milestones and royalties on net sales of the product. United to get exclusive worldwide rights to develop & commercialize Ralinepag
• The focus of the agreement is to develop Ralinepag for long-term success with an expectation to treat 10-000 patients annually from the 2020s to 2030s
• Ralinepag PO is a qd IP receptor agonist evaluated currently in P-III- indicated for the treatment of pulmonary arterial hypertension (PAH)

Ref: United Therapeutics | Image: PR Newswire